AD

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023

Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.

Key Points: 
  • Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.
  • Dr. Arella is a seasoned drug development and technology transfer expert and former drug scout for big pharmaceutical companies.
  • Dr. Arella served as Chief Scientist and member of Scientific Advisory Boards of small, medium and large pharmaceuticals companies since 1996.
  • Previously PurMinds' acting CSO, Dr. Arella was instrumental in guiding PurMinds' business strategy in drug development.

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023

With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.

Key Points: 
  • With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
  • Financial Results (for the quarter ending September 30, 2023)
    Cash and cash equivalents were $6.4 million.
  • Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

End-to-End Autonomous Driving and Modular Systems: Navigating the Future of ADAS Technology

Retrieved on: 
Thursday, November 9, 2023

In August 2023, Tesla showcased its AI-driven FSD V12, an end-to-end autonomous driving system, marking a significant milestone in autonomous driving.

Key Points: 
  • In August 2023, Tesla showcased its AI-driven FSD V12, an end-to-end autonomous driving system, marking a significant milestone in autonomous driving.
  • FSD V12 relies on large AI models, reducing the traditional codebase and achieving remarkable autonomous driving performance.
  • The report distinguishes between end-to-end autonomous driving and modular autonomous driving systems.
  • The Role of Large AI Models:
    The transition to urban NOA presents new challenges and corner cases for autonomous driving models.

Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia's Digital Twins to be Presented at SfN 2023

Retrieved on: 
Wednesday, November 8, 2023

SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.

Key Points: 
  • SOMERVILLE, Mass., Nov. 8, 2023 /PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from November 11-15, 2023 in Washington, D.C.
  • The presentation will focus on results from two Digital Twins derived from The Alzheimer's Disease Neuroimaging Initiative (ADNI), The Parkinson's Progression Markers Initiative (PPMI) and Genetic cohort study.
  • Specifically, Aitia Gemini Digital Twins for AD and PD together identified 20 genes related to cytoskeleton disorganization demonstrating a potential mechanism for patient variability in disease progression.
  • Details of the abstract and poster presentation are as follow:

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • This quarter, we have demonstrated proof of technology with our third clinical program, as well as our first proof of mechanism in our UB-312 program for Parkinson’s.
  • Results from the Phase 2a trial of UB-311 in patients with mild AD were published in The Lancet’s eBioMedicine in August 2023.
  • General and administrative expenses were $5.5 million and $7.3 million for the three months ended September 30, 2023, and 2022, respectively.

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

Retrieved on: 
Wednesday, November 8, 2023

AstraZeneca (AZN) is leveraging its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas (RNG) productivity through a planned expanded collaboration with Vanguard Renewables.

Key Points: 
  • AstraZeneca (AZN) is leveraging its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas (RNG) productivity through a planned expanded collaboration with Vanguard Renewables.
  • With an ambition of achieving a multiple fold increase in productivity, the collaboration aims to accelerate parity with fossil fuel-generated natural gas.
  • Drawing on AstraZeneca’s global manufacturing, supply chain, digital and scientific expertise, the companies plan to work together to increase RNG yield and generate a step change improvement in the production of RNG.
  • Technological improvements and enhanced production can increase access and cost-effectiveness of RNG, a current barrier to widespread renewable energy deployment.

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent progress.

Key Points: 
  • In September, we also proudly introduced our oral small molecule TREM2 agonist candidate, VG-3927, with the opening of our IND.
  • Cash Position: Cash, cash equivalents, and marketable securities were $133.6 million as of September 30, 2023, compared to $150.2 million as of June 30, 2023.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter ended September 30, 2023, were $6.9 million, compared to $4.8 million for the same period in 2022.
  • Net Loss: Loss from operations for the third quarter ended September 30, 2023, were $20.5 million, compared to $17.5 million for the same period in 2022.

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2023 financial results and recent portfolio and business updates. As of September 30, 2023, Alector’s cash, cash equivalents and investments totaled $588.9 million.

Key Points: 
  • “We’ve made significant clinical advancements in our late-stage immuno-neurology programs in the second half of 2023,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
  • In September 2023, Alector completed enrollment in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial, with data anticipated in the fourth quarter of 2024.
  • Collaboration revenue for the quarter ended September 30, 2023, was $9.1 million, compared to $14.9 million for the same period in 2022.
  • Total research and development expenses for the quarter ended September 30, 2023, were $46.3 million, compared to $48.3 million for the quarter ended September 30, 2022.

Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, November 7, 2023

Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.
  • ZURZUVAE is being developed and commercialized in collaboration with Biogen Inc. Sage also commercializes ZULRESSO® (brexanolone) CIV injection in the treatment of PPD.
  • Restructuring Expenses: Restructuring expenses were $33.6 million in the third quarter of 2023 due to the August 2023 corporate reorganization.
  • ET to review its third quarter 2023 financial results and discuss recent corporate updates.

ExtremeCloud Universal ZTNA Sets New Industry Standard for Simple, Secure Network Access

Retrieved on: 
Tuesday, November 7, 2023

Extreme Networks™, Inc. (Nasdaq: EXTR), a leader in cloud networking, today introduced ExtremeCloud™ Universal Zero Trust Network Access (ZTNA), the industry’s simplest, most complete network access solution.

Key Points: 
  • Extreme Networks™, Inc. (Nasdaq: EXTR), a leader in cloud networking, today introduced ExtremeCloud™ Universal Zero Trust Network Access (ZTNA), the industry’s simplest, most complete network access solution.
  • Offered as a subscription service for ExtremeCloud customers, Universal ZTNA is the first network security offering to integrate network, application and device access security within a single solution.
  • With Universal ZTNA from Extreme, organizations have an easy-to-manage access layer that spans anywhere that users connect to the network.
  • Universal ZTNA is another execution point against Extreme’s One Network, One Cloud strategy which dramatically reduces the cost and complexity of enterprise networking.